We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $875B
1-Year Est. Return 40.91%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MUX icon
11651
CALL
McEwen Inc
MUX
$1.15B
$66K ﹤0.01%
15,030
+9,450
+169% +$58.8K
RYAM icon
11652
Rayonier Advanced Materials
RYAM
$570M
$66K ﹤0.01%
25,057
-32,691
-57% -$147K
CLAA.WS
11653
DELISTED
Colonnade Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
CLAA.WS
$66K ﹤0.01%
510,299
+300
+0.1% +$88
EAR
11654
CALL
DELISTED
Eargo, Inc. Common Stock
EAR
$66K ﹤0.01%
4,385
+455
+12% +$21.5K
ACHV icon
11655
Achieve Life Sciences
ACHV
$779M
$65K ﹤0.01%
+13,275
New +$90K
BCAB icon
11656
PUT
BioAtla
BCAB
$5.15M
$65K ﹤0.01%
+458
New +$72.9K
BW icon
11657
CALL
Babcock & Wilcox
BW
$1.53B
$65K ﹤0.01%
10,700
-5,400
-34% -$37.8K
CISO
11658
PUT
CISO Global
CISO
$12.2M
$65K ﹤0.01%
1,207
-566
-32% -$43.9K
CLSD
11659
CALL
DELISTED
Clearside Biomedical
CLSD
$65K ﹤0.01%
2,933
+1,160
+65% +$28.2K
HRTX icon
11660
PUT
Heron Therapeutics
HRTX
$63.9M
$65K ﹤0.01%
23,200
-41,500
-64% -$167K
PAYO icon
11661
PUT
Payoneer
PAYO
$2.42B
$65K ﹤0.01%
16,600
-29,500
-64% -$132K
PLX icon
11662
Protalix BioTherapeutics
PLX
$179M
$65K ﹤0.01%
+59,915
New +$70.1K
PRCH icon
11663
PUT
Porch Group
PRCH
$1.97B
$65K ﹤0.01%
25,300
-4,100
-14% -$17K
TEF
11664
PUT
DELISTED
Telefonica
TEF
$65K ﹤0.01%
12,700
-31,790
-71% -$155K
TGS icon
11665
CALL
Transportadora de Gas del Sur
TGS
$4.23B
$65K ﹤0.01%
12,600
+300
+2% +$1.9K
FGH
11666
CALL
DELISTED
FG Group Holdings Inc.
FGH
$65K ﹤0.01%
27,100
-6,500
-19% -$18.8K
CVT
11667
DELISTED
Cvent Holding Corp. Common Stock
CVT
$65K ﹤0.01%
+13,897
New +$81K
PHAS
11668
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$65K ﹤0.01%
+107,953
New +$103K
FINV
11669
PUT
FinVolution Group
FINV
$1.03B
$64K ﹤0.01%
13,500
-200
-1% -$807
HIPO icon
11670
PUT
Hippo Holdings
HIPO
$872M
$64K ﹤0.01%
2,932
-2,128
-42% -$78.6K
IBIO icon
11671
CALL
iBio
IBIO
$71M
$64K ﹤0.01%
481
+68
+16% +$10.2K
ORLA
11672
CALL
DELISTED
Orla Mining
ORLA
$64K ﹤0.01%
23,300
+11,800
+103% +$48.5K
ACHV icon
11673
CALL
Achieve Life Sciences
ACHV
$779M
$63K ﹤0.01%
13,000
-37,200
-74% -$252K
ARHS icon
11674
PUT
Arhaus
ARHS
$1.39B
$63K ﹤0.01%
+14,000
New +$91.7K
DBVT
11675
CALL
DBV Technologies
DBVT
$881M
$63K ﹤0.01%
2,480
+1,270
+105% +$21.2K

Similar funds

Citadel Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Citadel Advisors held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Citadel Advisors's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Citadel Advisors's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Citadel Advisors added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Citadel Advisors's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Citadel Advisors fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Citadel Advisors's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Citadel Advisors opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Citadel Advisors's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.